Cargando…

Serological response to nifurtimox in adult patients with chronic Chagas disease: An observational comparative study in Argentina

Nifurtimox is indicated in Chagas disease but determining its effectiveness in chronic disease is hindered by the length of time needed to demonstrate negative serological conversion. We manually reviewed long-term follow-up data from hospital records of patients with chronic Chagas disease (N = 1,4...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vizcaya, David, Grossmann, Ulrike, Kleinjung, Frank, Zhang, Ruiping, Suzart-Woischnik, Kiliana, Seu, Sandra, Ramirez, Teresa, Colmegna, Leylen, Ledesma, Oscar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489720/ https://www.ncbi.nlm.nih.gov/pubmed/34606501 http://dx.doi.org/10.1371/journal.pntd.0009801

Ejemplares similares

ELISA F29 –A therapeutic efficacy biomarker in Chagas disease: Evaluation in pediatric patients treated with nifurtimox and followed for 4 years post-treatment
por: Rivero, Rocio, et al.
Publicado: (2023)

Serological and parasitological response in chronic Chagas patients 3 years after nifurtimox treatment
por: Jackson, Yves, et al.
Publicado: (2013)

Efficacy and Safety of Nifurtimox in Pediatric Patients with Chagas Disease: Results at 4-Year Follow-Up in a Prospective, Historically Controlled Study (CHICO SECURE)
por: Altcheh, Jaime, et al.
Publicado: (2023)

Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States
por: Forsyth, Colin J., et al.
Publicado: (2016)

Tolerance to nifurtimox and benznidazole in adult patients with chronic Chagas’ disease
por: Jackson, Yves, et al.
Publicado: (2020)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
por: Rolon, Miriam, et al.
Publicado: (2022)

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
por: Altcheh, Jaime, et al.
Publicado: (2021)

Serum biomarkers predictive of cure in Chagas disease patients after nifurtimox treatment
por: Santamaria, Cynthia, et al.
Publicado: (2014)

Safety Profile of Nifurtimox and Treatment Interruption for Chronic Chagas Disease in Colombian Adults
por: Olivera, Mario Javier, et al.
Publicado: (2015)

Detection of Trypanosoma cruzi by PCR in adults with chronic Chagas disease treated with nifurtimox
por: Vergara, Camilo, et al.
Publicado: (2019)

Negligible exposure to nifurtimox through breast milk during maternal treatment for Chagas Disease
por: Moroni, Samanta, et al.
Publicado: (2019)

Biopharmaceutical Characteristics of Nifurtimox Tablets for Age‐ and Body Weight‐Adjusted Dosing in Patients With Chagas Disease
por: Stass, Heino, et al.
Publicado: (2020)

Effectiveness of Nifurtimox in the Treatment of Chagas Disease: a Long-Term Retrospective Cohort Study in Children and Adults
por: Falk, N., et al.
Publicado: (2022)

Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands
por: Voss, Annemarie, et al.
Publicado: (2023)

Follow-up of an Asymptomatic Chagas Disease Population of Children after Treatment with Nifurtimox (Lampit) in a Sylvatic Endemic Transmission Area of Colombia
por: Bianchi, Fiorella, et al.
Publicado: (2015)

2128. Lack of Congenital Transmission in Infants Born of Female Patients with Chagas Disease who Became Pregnant During a Nifurtimox Study (CHICO and CHICO SECURE Study)
por: Jaime, A L T C H E H, et al.
Publicado: (2022)

Nifurtimox Inhibits the Progression of Neuroblastoma in vivo
por: Kong, Eryan, et al.
Publicado: (2019)

Quantification of Immunoglobulin G against Trypanosoma cruzi in Individuals with Chronic Chagas Disease Treated with Nifurtimox and Evaluated in Prolonged Follow-Up
por: Muñoz, Gabriela, et al.
Publicado: (2019)

Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK
por: García Rodríguez, Luis Alberto, et al.
Publicado: (2019)

Limited evidence on persistence with anticoagulants, and its effect on the risk of recurrence of venous thromboembolism: a systematic review of observational studies
por: Vora, Pareen, et al.
Publicado: (2016)

Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox
por: Lang, Dieter, et al.
Publicado: (2022)

Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina
por: Niborski, Leticia L, et al.
Publicado: (2016)

Correction to “Structural and Mechanistic Investigation of the Unusual Metabolism of Nifurtimox”
por: Lang, Dieter, et al.
Publicado: (2023)

Reinfestation Sources for Chagas Disease Vector, Triatoma infestans, Argentina
por: Cecere, María C., et al.
Publicado: (2006)

Characteristics and Adverse Events of Patients for Whom Nifurtimox Was Released Through CDC-Sponsored Investigational New Drug Program for Treatment of Chagas Disease — United States, 2001–2021
por: Abbott, Andrew, et al.
Publicado: (2022)

Trypanosoma cruzi in Persons without Serologic Evidence of Disease, Argentina
por: Salomone, Oscar A., et al.
Publicado: (2003)

Cost-Effectiveness of Chagas Disease Vector Control Strategies in Northwestern Argentina
por: Vazquez-Prokopec, Gonzalo M., et al.
Publicado: (2009)

Genotoxicity Revaluation of Three Commercial Nitroheterocyclic Drugs: Nifurtimox, Benznidazole, and Metronidazole
por: Buschini, Annamaria, et al.
Publicado: (2009)

Nifurtimox Is Effective Against Neural Tumor Cells and Is Synergistic with Buthionine Sulfoximine
por: Du, Michael, et al.
Publicado: (2016)

720. Efficacy of Nifurtimox + Eflornithine in the Treatment of African Trypanosomiasis. Systematic Review
por: Hidalgo, Jessica, et al.
Publicado: (2021)

The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis
por: Burkill, Sarah, et al.
Publicado: (2019)

Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis
por: Gill, Simrat, et al.
Publicado: (2022)

Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden
por: Hakkarainen, Katja Marja, et al.
Publicado: (2020)

Nifurtimox Activation by Trypanosomal Type I Nitroreductases Generates Cytotoxic Nitrile Metabolites
por: Hall, Belinda S., et al.
Publicado: (2011)

Trypanosoma cruzi Mitochondrial Peroxiredoxin Promotes Infectivity in Macrophages and Attenuates Nifurtimox Toxicity
por: Specker, Gabriela, et al.
Publicado: (2022)

Conventional serological performance in diagnosis of Chagas’ disease in southern Brazil
por: Araújo, Anelise Bergmann, et al.
Publicado: (2013)

Sensibilidad in vitro a benznidazol, nifurtimox y posaconazol de cepas de Trypanosoma cruzi de Paraguay
por: Acosta, Nidia, et al.
Publicado: (2020)

Urban Chagas disease in children and women in primary care centres in Buenos Aires, Argentina
por: Moscatelli, Guillermo, et al.
Publicado: (2015)

Urban infestation by Triatoma infestans (Hemiptera: Reduviidae), an overlooked phenomena for Chagas disease in Argentina
por: Provecho, Yael Mariana, et al.
Publicado: (2021)

Nifurtimox plus Eflornithine for Late-Stage Sleeping Sickness in Uganda: A Case Series
por: Checchi, Francesco, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_76jghvkqqcb6sgg75192a1hdno